INmune Bio Inc., a clinical-stage company specializing in inflammation and immunology, has announced promising results from a study involving their drug XPro™. The study, conducted in collaboration with Kirsty Dixon, PhD, Associate Professor of Surgery at Virginia Commonwealth University, was presented at the Keystone Symposia's Neurodegeneration section. The findings indicate that XPro™, a next-generation inhibitor of tumor necrosis factor (TNF), effectively reduces amyloid deposition and enhances brain function in an animal model of Alzheimer's disease post-traumatic brain injury $(TBI)$. These results suggest potential benefits in treating Alzheimer's-like pathology and preserving cognitive function in patients with traumatic brain injuries. The drug is currently in clinical trials and could offer a novel approach to addressing neuroinflammation and its effects on neurological health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.